22 results
8-K
EX-10.1
CRVO
CervoMed Inc
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
(as defined in Section 4.13), trade secret, innovation, trademark, data, database, or the like, whether or not patentable, together with all
8-K
EX-10.2
CRVO
CervoMed Inc
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
, software, work of authorship or other Works (as defined in Section 4.13), trade secret, innovation, trademark, data, database, or the like, whether
8-K
EX-10.3
CRVO
CervoMed Inc
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
of authorship or other Works (as defined in Section 4.13), trade secret, innovation, trademark, data, database, or the like, whether or not patentable, together
8-K
EX-10.1
0pjykdus4gepgxjv5e0
17 Nov 23
Entry into a Material Definitive Agreement
5:03pm
8-K/A
EX-99.3
gmg 611t1i
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K
bem6m7 etc21
17 Aug 23
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
4:15pm
8-K
EX-10.1
6pkpvj 74qvlqev0vq
28 Jun 22
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
4:13pm
8-K
EX-10.1
yoa4gcpmo9 am4
20 Oct 20
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
5:30pm
8-K
EX-10.1
cpxntv7d8uhcf2radxfo
25 Sep 20
Diffusion Pharmaceuticals Strengthens Management Team with Appointmentof William Elder as General Counsel and Corporate Secretary
4:57pm
8-K
EX-10.2
y5jqcs
9 Sep 20
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
9:30am